Evidence map›Paper›PMID 39821609›Full record

ArticleJournal of inherited metabolic disease2025

Speech, Language and Non-verbal Communication in CLN2 and CLN3 Batten Disease.

Lottie D Morison, Ineka T Whiteman, Adam P Vogel, Lisa Tilbrook, Michael C Fahey, Ruth Braden, Joanna Bredebusch, Michael S Hildebrand, Ingrid E Scheffer, Angela T Morgan

Abstract read
In one paragraph

Article in Journal of inherited metabolic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lottie D MorisonSpeech and Language, Murdoch Children's Research Institute, Parkville, Victoria, Australia.ORCID 0000-0003-2822-6522
Ineka T WhitemanBatten Disease Support and Research Association Australia, Shelley Beach, New South Wales, Australia.
Adam P VogelDepartment of Audiology and Speech Pathology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-3505-2631
Lisa TilbrookBatten Disease Support and Research Association Australia, Shelley Beach, New South Wales, Australia.
Michael C FaheyBatten Disease Support and Research Association Australia, Shelley Beach, New South Wales, Australia.
Ruth BradenSpeech and Language, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Joanna BredebuschDepartment of Audiology and Speech Pathology, The University of Melbourne, Parkville, Victoria, Australia.
Michael S HildebrandEpilepsy Research Centre, The University of Melbourne, Heidelberg, Victoria, Australia.ORCID 0000-0003-2739-0515
Ingrid E SchefferBatten Disease Support and Research Association Australia, Shelley Beach, New South Wales, Australia.ORCID 0000-0002-2311-2174
Angela T MorganSpeech and Language, Murdoch Children's Research Institute, Parkville, Victoria, Australia.ORCID 0000-0003-1147-7405

Funding

Australian Research Council 220100253Batten Disease Support and Research Association Australia 2022National Health and Medical Research Council 1105008National Health and Medical Research Council 1172897National Health and Medical Research Council 1195955National Health and Medical Research Council 2006841National Health and Medical Research Council 2015727National Health and Medical Research Council 2022156Victorian Government's Operational Infrastructure Support Program
6 · The paper itself

Abstract

CLN2 and CLN3 diseases, the most common types of Batten disease (also known as neuronal ceroid lipofuscinosis), are childhood dementias associated with progressive loss of speech, language and feeding skills. Here we delineate speech, language, non-verbal communication and feeding phenotypes in 33 individuals (19 females) with a median age of 9.5 years (range 3-28 years); 16 had CLN2 and 17 CLN3 disease; 8/15 (53%) participants with CLN2 and 8/17 (47%) participants with CLN3 disease had speech and language impairments prior to genetic diagnosis. At the time of study all participants, bar one, had language impairments. The remaining participant with typical language was tested at age 3 years, following pre-symptomatic enzyme replacement therapy (ERT) from age 9 months. CLN2 and CLN3 disease had different profiles. For CLN2 disease, all affected individuals showed language impairment with dysarthria; older individuals with classical disease progressively became non-verbal. For CLN3 disease, the presentation was more heterogeneous. Speech impairment was evident early in the disease course, with dysarthria (13/15, 87%), often manifesting as neurogenic stuttering (5/15, 33%). Participants with CLN2 disease had comparable expressive and receptive language skills (p > 0.99), yet participants with CLN3 disease had stronger expressive language than receptive language skills (p = 0.004). Speech, cognitive and language impairment and adaptive behaviour showed progressive decline in both diseases. Individuals with pre-symptomatic ERT or atypical CLN2 disease were less impaired. Challenging behaviours were common in CLN3 (11/17, 65%), but less frequent in CLN2 (4/16, 25%) disease. Individuals with Batten disease require tailored speech therapy incorporating communication partner training utilising environment adaptations and informal communication behaviours.

Indexed as

Membrane GlycoproteinsMolecular ChaperonesNeuronal Ceroid-LipofuscinosesSpeechAdolescentAdultChildChild, PreschoolCommunicationFemaleHumansLanguageMalePhenotypeSpeech DisordersYoung AdultCLN3 protein, humanMembrane GlycoproteinsMolecular ChaperonesBatten diseasecerliponase alfaCLN2CLN3enzyme replacement therapylanguageneuronal ceroid lipofuscinosesspeech

Identifiers

PMID39821609
PMCPMC11739554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.